Due to dual expression of mesothelin (MSLN) in both lung cancer and normal mesothelium, the development of mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism can selectively kill MSLN(+)A*02(-) malignant cells [98]. This evidence concerns the gene MSLN and lung carcinoma.